Publications
Publications
Show Results For
- All HBS Web
(1,278)
- Faculty Publications (509)
- June 2004
- Case
Aventis SA (B): A Company is Born
By: Joshua D. Margolis and Carin-Isabel Knoop
Supplements the (A) case. View Details
- June 2004 (Revised June 2006)
- Supplement
Vertex Pharmaceuticals: R&D Portfolio Management (A)
By: Gary P. Pisano, Lee Fleming and Eli Strick
Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will... View Details
- May 2004 (Revised June 2004)
- Case
Brief Biographical Note on P. Roy Vagelos
By: Nitin Nohria and Bridget Gurtler
Provides background biographical information on P. Roy Vagelos, chief executive officer of Merck Pharmaceuticals. Teaching Purpose: To chart the development of a leader in the pharmaceutical industry. View Details
- March 2004 (Revised July 2004)
- Case
UCB: Managing Information for Globalization and Innovation (A) (Abridged)
By: F. Warren McFarlan and Brian DeLacey
A medium-size European manufacturer of pharmaceuticals and chemicals faces a number of information strategy issues. The case focuses on the issues of coordinating international IT activities and day-to-day operations as well as balancing the company's IT applications... View Details
- August 2003
- Teaching Note
Pharmacyclics: Financing Research and Development (TN)
By: Malcolm P. Baker and Richard S. Ruback
Teaching Note for (9-201-056). View Details
- August 2003 (Revised August 2006)
- Case
New Sector Alliance (A): An Entry into Health Care?
By: Regina E. Herzlinger, Stacy Smollin Schwartz and Jeffrey Cronin
Describes the structure of the U.S. health care system and presents a study of a nonprofit consulting firm that hopes to enter the health care system. Includes descriptions of hospitals, doctors, insurers, medical technology providers, medical devices, pharmaceuticals,... View Details
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (C)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (D)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
- June 2003 (Revised March 2008)
- Case
Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene
By: Regina E. Herzlinger and Marc Aquino
Personalized medicine requires the identification of mutated genes. Schering-Plough's search for the one related to asthma requires finding families with the disease. Examines the industry that helps conduct such research, including contract research organizations. View Details
- June 2003 (Revised May 2006)
- Case
Cipla
By: Rohit Deshpande and Laura Winig
The head of Cipla, a $325-million-dollar Indian pharmaceutical company and seller of low-cost AIDS drugs to South Africa, must decide what to do about Cipla's future. With India poised to enforce international patents in only two years, much of Cipla's product line... View Details
- June 2003
- Teaching Note
Discovering the Future: R&D Strategy at Merck (TN)
By: Gary P. Pisano
Teaching Note for (9-601-086). View Details
Keywords: Pharmaceutical Industry
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (B)
By: Sandra J. Sucher and Stacy McManus
When Dr. Daniel Vasella learned of the early Phase 1 trial results, he immediately decided what course of action Novartis would take. Students will be able to examine and assess the concrete steps, and the rationale behind them, that Novartis took in response to this... View Details
- February 2003 (Revised April 2004)
- Case
Pharmaceutical Industry, The: Challenges in the New Century
By: Stephen P. Bradley and James Weber
Provides a broad overview of the numerous internal and external forces that were driving change in the global pharmaceutical industry in 2003. These forces--including downward price pressures, political and social pressures, increased development costs, new... View Details
- February 2003 (Revised August 2005)
- Case
UCB (A): Managing Information for Globalization and Innovation
By: F. Warren McFarlan and Brian DeLacey
This case presents a complex total MIS strategy case for a $3 billion European pharmaceutical/chemicals company based in Brussels. It covers corporate strategy alignment of IT portfolio, IT operations issues, and global coordination of IT. View Details
- Article
Discontinuities and Senior Management: Assessing the Role of Recognition in Pharmaceutical Firm Response to Biotechnology
By: Rebecca M. Henderson, Sarah Kaplan and Fiona Murray
- December 2002
- Teaching Note
Abgenix and the XenoMouse (TN)
Teaching Note for (501-061). View Details
- December 2002
- Article
Knowledge Seeking and Location Choice of Foreign Direct Investment in the United States
By: Juan Alcacer and Wilbur Chung
To what extent do firms go abroad to access technology available in other locations? This paper examines whether and when state technical capabilities attract foreign investment in manufacturing from 1987-1993. We find that on average state R&D intensity does not... View Details
- November 2002
- Compilation
Four Principles of Biomedical Ethics: Definitions and Examples
By: Sandra J. Sucher
Introduces four principles of biomedical ethics, excerpted from Principles of Biomedical Ethics, Tom L. Beauchamp and James F. Childress (Oxford University Press, 2001). The principles provide a conceptual framework for the analysis and resolution of moral problems... View Details
- October 2002 (Revised June 2003)
- Background Note
New Frontiers in Target Discovery and Validation
By: Regina E. Herzlinger, Niv Caviar, Jon Chatterton and Andrea Lynn
Explains Immusol and Novartis's technology. View Details